Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01744912

Recruitment Status : Completed

First Posted : December 7, 2012

Last Update Posted : October 13, 2014

Sponsor:

Information provided by (Responsible Party):

TG Therapeutics, Inc.

Results Submitted - Not Posted on ClinicalTrials.gov

Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

Recruitment Status :	Completed
Actual Primary Completion Date :	May 2014
Actual Study Completion Date :	October 2014

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	November 18, 2015	December 21, 2015
2	August 7, 2019	August 21, 2019
3	September 3, 2019	September 23, 2019

To Top